Results 161 to 170 of about 124,779 (298)

Advances and perspectives in animal models of human hepatitis A virus

Animal Models and Experimental Medicine, EarlyView.
Following HAV infection, humans, non‐human primates, and Ifnar1−/− mice develop characteristic manifestations of hepatitis A, including fecal viral shedding, elevated serum ALT levels, and inflammatory cell infiltration in the liver. In contrast, HAV‐infected human liver chimeric mice exhibit fecal viral shedding but do not develop clinical features of
Jian Li, Pei‐Yu Jiang, Hui Zhao, Cheng‐Feng Qin   +3 more
wiley   +1 more source

Synthetic O‐Polysaccharide Backbone Units for a Single Antigen Vaccine Against Two Major Non‐Typhoidal Salmonella Serovars

Angewandte Chemie, EarlyView.
A modular strategy was developed to synthesize tri‐, hexa‐, and nona‐saccharides representing repeating units of the conserved O‐polysaccharide backbone of Salmonella. Conjugates of these glycans to bacteriophage Qβ induced strong IgG responses in mice and rabbits. Antibodies elicited recognized native O‐polysaccharides and conferred protection against
Xingling Pan, Changxin Huo, Soham Maity, Herbert Kavunja, Rachel Moszyk, Cameron Talbot, Scott M. Baliban, Xuefei Huang   +7 more
wiley   +2 more sources

Editorial: Epitope Discovery and Synthetic Vaccine Design

Frontiers in Immunology, 2018
Clarisa Beatriz Palatnik-de-Sousa, Clarisa Beatriz Palatnik-de-Sousa, Irene da Silva Soares, Daniela Santoro Rosa, Daniela Santoro Rosa   +4 more
doaj   +1 more source

A systematic review on vaccine developmental approaches: Evaluating efficacy, and addressing challenges of infectious diseases in the post-COVID-19 era. [PDF]

Virus Res
Sithole MN, Khan MR, Mohammed HA, Khan RA, Naik K, Choonara YE.   +5 more
europepmc   +1 more source

Animal research in the UK: Regulation, implementation, welfare and development of new approach methodologies

Animal Models and Experimental Medicine, EarlyView.
Scientific research with animals in the UK is regulated by the Animals (Scientific Procedures) Act 1986 with the National Centre for the Replacement, Refinement and Reduction of Animals in Research providing support for best practice and facilitating development of new approach methodologies.
Ewan St. John Smith, James Bussell, Maggie Gentry, Elliot Lilley, Cathy Merry, Judy MacArthur Clark, William Reynolds   +6 more
wiley   +1 more source

A Deep‐Red‐Absorbing Osmium(II) Complex as a Photosensitizer for Photodynamic Therapy Inducing Immunogenic Cell Death

Angewandte Chemie, EarlyView.
A deep‐red‐excited osmium(II) photosensitizer (Os2) induces immunogenic cell death (ICD) under 740 nm irradiation and triggers robust anti‐tumor immune responses both in vitro and in vivo. ABSTRACT Immunogenic cell death (ICD), which converts tumor cells into their own vaccine, plays a pivotal role in the development of novel anticancer therapies. Here,
Yiyi Zhang, Pierre Mesdom, Eduardo Izquierdo‐García, João P. M. António, Ruonan Gao, Bruno Saubaméa, Johanne Seguin, Morgane Moinard, Philippe Arnoux, Céline Frochot, Kevin Cariou, Bich‐Thuy Doan, Gilles Gasser   +12 more
wiley   +2 more sources

An immunoinformatic strategy for developing peptide vaccines against autoimmune diseases by targeting cross-reactive bacterial antigens. [PDF]

Pak J Med Sci
Tipu HN, Alam M.
europepmc   +1 more source

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

Advanced NanoBiomed Research, EarlyView.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

Nonviral Gold Nanoparticle‐Mediated Delivery of CRISPR‐Cas9 Ribonucleoprotein and Long DNA Transgenes Into Primary Blood Cells

Advanced NanoBiomed Research, EarlyView.
CRISPR/Cas9 has revolutionized the field of gene therapy, but delivery remains an outstanding issue. We propose a nonviral gold‐nanoparticle platform for co‐delivery of CRISPR/Cas9 ribonucleoprotein and long 2.1 kilobase dsDNA transgene constructs. This CRISPR‐AuNP is inexpensive to produce and mediate gene editing and DNA delivery in T cells and CD34+
Rachel A. Cunningham, Karthikeya S. V. Gottimukkala, Daniel D. Lane, Katrina Poljakov, Patricia Lipson, Mark R. Enstrom, Alessandro Rizzi, Aude G. Chapuis, Jennifer E. Adair   +8 more
wiley   +1 more source

Immunomodulation by glycosylation: bridging glycobiology to adaptive immunity and therapeutic innovation. [PDF]

Front Immunol
Ding S, Wang H, Han Z, Hong S.
europepmc   +1 more source